Document is current
Any future updates will be listed below
-
Authors
Schaunaman, Niccolette
Cervantes, Diana
Nichols, Taylor
Numata, Mari
Ledford, Julie G.
Kraft, Monica
Chu, Hong Wei
-
Funding
Funding for this research was provided by:
National Institutes of Health (U19AI125357)
National Institutes of Health (U19AI125357)
National Institutes of Health (U19AI125357)
National Institutes of Health (U19AI125357)
National Institutes of Health (U19AI125357)
National Institutes of Health (U19AI125357)
National Institutes of Health (U19AI125357)
- License Information
-
More Information
Article History
Received: 26 March 2024
Accepted: 23 April 2024
First Online: 3 May 2024
Declarations
:
: The animal study protocol was approved by the Institutional animal care and use committee (IACUC) of National Jewish Health (AS2792-03-26).
: Not applicable.
: Drs. Ledford and Kraft are co-founders of RaeSedo, LLC, a company to develop novel peptidomimetic based therapeutics derived from an active area of SP-A. No peptidomimetic studies are reported in this manuscript. All other authors declare no conflict of interest.
